Cellectis Launches Ectycell Subsidiary Dedicated to Stem Cells Applications
"Cellectis' core technologies will have a major impact on the stem cell field", stated David Sourdive, CEO of Ectycell. "We are tackling important issues here, such as reducing the high attrition rate in drug development by using early-stage assays that better predict a molecule's effect on the organism as a whole or on a genetically diverse population. We also may have the opportunity to open new paths for regenerative medecine - especially for pathologies like Alzheimer's and Parkinson's diseases".
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.